Skip to content
  • Friday, 30 October 2026
  • 11:41 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 18, 2026 0

Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 11, 2026 0

Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…

Read More
Laboratory Automation & Robotics

Lilly’s retatrutide shows 28.3% weight loss, but increased side effects

Lana Keisha Jul 2, 2026 0

Eli Lilly’s experimental triple hormone receptor agonist, retatrutide, has recently captured significant attention within the medical and pharmaceutical communities following…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 1, 2026 0

Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Retatrutide Demonstrates Superior Weight Loss Efficacy Amidst Elevated Side Effect Profile in Phase 3 Trials

Lana Keisha Jun 25, 2026 0

INDIANAPOLIS, IN – Eli Lilly and Company has announced groundbreaking Phase 3 trial results for its investigational drug, retatrutide, a…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jun 22, 2026 0

The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…

Read More
Pharmaceutical R&D

Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy

Teuku Ryan Jun 18, 2026 0

NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Retatrutide Shows Unprecedented Weight Loss, But Increased Side Effects Raise Tolerability Concerns

Lana Keisha Jun 16, 2026 0

Eli Lilly and Company’s investigational drug, retatrutide, a pioneering triple hormone receptor agonist, has demonstrated an average weight loss of…

Read More
Laboratory Automation & Robotics

Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo

Lana Keisha Jun 15, 2026 0

Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Retatrutide Demonstrates Unprecedented Weight Loss with Notable Side Effect Profile in Phase 3 Trials

Lana Keisha May 29, 2026 0

Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…

Read More

Posts pagination

1 2
New insights into Alzheimer’s disease emerge as researchers map the three-dimensional architecture of the genome within the human brain.Landmark Research Reveals How Aging Sperm Accumulate Harmful Genetic Mutations Through Internal Natural SelectionThe Pigeon’s Inner Compass: How Liver Cells Detect Earth’s Magnetic FieldUnlocking the Power of Personal AI: Five Engaging Projects with OpenClaw
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
The oral exposure challenge in PROTACs: What drug developers need to solve earlyThe Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALSESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial CancerThe Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Oct 28, 2026
Environmental & Analytical Chemistry
The Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALS
Abdurrohim Arsyad Oct 28, 2026
Pharmaceutical R&D
ESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial Cancer
Teuku Ryan Oct 28, 2026
Molecular & Cell Biology
The Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
Angie Faith Oct 28, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ